GERN - NASDAQ
Geron Corporation
$1.16
-0.85%Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
At a Glance
Live SnapshotGeron Corporation Management Team
Mr. James Ziegler M.B.A.
Executive Vice President & Chief Commercial Officer
Compensation
$618,670
Dr. Faye Feller M.D.
Executive Vice President & Chief Medical Officer
Dr. Andrew J. Grethlein Ph.D.
Executive Vice President & Chief Operating Officer
Compensation
$977,476
Ms. Shannon T. Odam
Executive Vice President & Chief People Officer
Dr. Joseph Emile Eid M.D.
Executive Vice President of Research & Development
Compensation
$304,098
Ms. Michelle J. Robertson
Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer
Compensation
$846,376
Mr. Scott Samuels
Executive Vice President, Chief Legal Officer & Secretary
Compensation
$485,317
Ms. Dawn Carter Bir
Interim President & Chief Executive Officer and Director
Compensation
$64,158
Ms. Aron Feingold
Vice President of Investor Relations & Corporate Communications
Geron Corporation Insider Positioning
During the last 12 months, insiders have purchased $3.81M and sold $19K worth of GERN shares, resulting in $3.79M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
9.9K
19.12K
-19K
-$19K
6-9 Months
3.0M
3.81M
0
0.00
+3.8M
+$3.81M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Elnawawi Ahmed
Officer: Evp, Chief Commercial Officer
$3.81M
Top Sellers
Robertson Michelle
Officer: Evp, Chief Financial Officer
$19K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $3.79M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
GERN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 27, 2024 | May 09, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 12, 2023 | April 12, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 22, 2022 | May 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 22, 2021 | May 11, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 14, 2020 | June 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 22, 2019 | June 06, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 30, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 24, 2017 | May 09, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.